$1.19
4.80% yesterday
NYSE, Nov 13, 10:13 pm CET
ISIN
US44486Q1031
Symbol
HUMA

Humacyte Stock price

$1.19
-0.57 32.39% 1M
-0.54 31.21% 6M
-3.86 76.44% YTD
-4.15 77.72% 1Y
-1.96 62.22% 3Y
-8.48 87.69% 5Y
-8.48 87.69% 10Y
-8.48 87.69% 20Y
NYSE, Closing price Thu, Nov 13 2025
-0.06 4.80%
ISIN
US44486Q1031
Symbol
HUMA
Industry

Key metrics

Basic
Market capitalization
$222.9m
Enterprise Value
$202.1m
Net debt
positive
Cash
$38.0m
Shares outstanding
156.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
271.8 | 60.1
EV/Sales
246.4 | 54.5
EV/FCF
negative
P/B
55.0
Financial Health
Equity Ratio
-38.2%
Return on Equity
282.9%
ROCE
-94.4%
ROIC
-118.2%
Debt/Equity
4.3
Financials (TTM | estimate)
Revenue
$820.0k | $3.7m
EBITDA
$-103.8m | $-60.5m
EBIT
$-111.1m | $-102.2m
Net Income
$-58.7m | $-54.0m
Free Cash Flow
$-105.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-4.3% | 43.4%
EBIT
-4.1% | 10.4%
Net Income
58.1% | 63.8%
Free Cash Flow
-28.7%
Margin (TTM | estimate)
Gross
56.0%
EBITDA
-12,693.4% | -1,630.8%
EBIT
-13,587.3%
Net
-7,178.6% | -1,454.6%
Free Cash Flow
-12,949.1%
More
EPS
$-0.4
FCF per Share
$-0.7
Short interest
19.3%
Employees
219
Rev per Employee
$0.0
Show more

Is Humacyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Humacyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Humacyte forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Humacyte forecast:

Buy
85%
Hold
15%

Financial data from Humacyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.82 0.82
-
100%
- Direct Costs 0.36 0.36
-
44%
0.46 0.46
-
56%
- Selling and Administrative Expenses 31 31
33% 33%
3,741%
- Research and Development Expense 60 60
28% 28%
7,360%
-104 -104
4% 4%
-12,662%
- Depreciation and Amortization 7.31 7.31
1% 1%
891%
EBIT (Operating Income) EBIT -111 -111
4% 4%
-13,554%
Net Profit -59 -59
58% 58%
-7,161%

In millions USD.

Don't miss a Thing! We will send you all news about Humacyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Humacyte Stock News

Neutral
GlobeNewsWire
about 20 hours ago
DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company's acellular tissue engineered vessel (ATEV™) that are scheduled for the 52nd Annual Symposium on Vascular and Endovascu...
Neutral
Seeking Alpha
one day ago
Humacyte, Inc. ( HUMA ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Laura Niklason - Founder, President, CEO & Director Dale Sander - CFO, Chief Corporate Development Officer & Treasurer Conference Call Participants Thomas Johnson - Lifesci Advisors, LLC Sneha Muthe - Barclays Bank PLC, Research Division Iseult McMahon - BTIG, LLC, Research Division Joshua Jennings ...
Neutral
GlobeNewsWire
2 days ago
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement -  - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in mu...
More Humacyte News

Company Profile

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Head office United States
CEO Laura Niklason
Employees 219
Founded 2004
Website humacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today